Physician profile
Larissa Lempert
NPI 1912182619
$1,027.86
in general payments reported to CMS, 2019-2025
16 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.81 · 2020: $22.74 · 2024: $68.39 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $224.95 | 2025 | Rexulti |
| Lundbeck LLC | $168.80 | 2024-2025 | Vyepti, Rexulti |
| Abbvie INC. | $114.54 | 2025 | |
| Azurity Pharmaceuticals, INC. | $100.02 | 2025 | Horizant |
| Pfizer INC. | $75.88 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $60.57 | 2025 | Crexont |
| Mdd US Operations, LLC | $46.48 | 2025 | |
| Biogen, INC. | $45.90 | 2024-2025 | Vumerity |
| Vanda Pharmaceuticals INC. | $29.51 | 2025 | Ponvory |
| Supernus Pharmaceuticals, INC. | $24.47 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.46 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $23.79 | 2025 | Austedo Xr |
| Scilex Pharmaceuticals INC. | $22.94 | 2025 | |
| Allergan, INC. | $22.74 | 2020 | |
| Genzyme Corporation | $22.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Lempert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.